Tasidotin hydrochloride

DRACPC ID  DRACPC0105

Active Ingredients   Tasidotin hydrochloride

Description  A synthetic analogue of dolastatin 15. Dolastatins are a group of structurally unique peptides originally isolated from a sea hare, Dolabella auricularia, which seem to inhibit tubulin polymerization and mitosis.

Synonyms  ILX-651; Tasidotin HCl; Tasidotin Hydrochloride

Type  Small Molecule

Disease  Melanoma,Non-Small-Cell Lung Carcinoma, Prostate Cancer

Classification

  

Peptide and derivative

Structure Information


Molecular Formula  C32H59ClN6O5

Molecular Weight  643.3

Active Sequence  VVXPP

Sequence Length  5

Modification  X=N(Me)Val, C-terminal Me2, N-terminal NHtBu.HCl

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-N-tert-butyl-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride

InChI  InChI=1S/C32H58N6O5.ClH/c1-19(2)24(33-28(40)25(20(3)4)35(10)11)30(42)36(12)26(21(5)6)31(43)38-18-14-16-23(38)29(41)37-17-13-15-22(37)27(39)34-32(7,8)9;/h19-26H,13-18H2,1-12H3,(H,33,40)(H,34,39);1H/t22-,23-,24+,25-,26-;/m0./s1

InChI_Key OOKIODJYZSVHDO-JJMGAAHBSA-N

SMILES  CC(C)[C@H](N(C)C)C(N[C@H](C(C)C)C(N(C)[C@H](C(N(CCC1)[C@]1([H])C(N2CCC[C@]([H])2C(NC(C)(C)C)=O)=O)=O)C(C)C)=O)=O.[H]Cl

External Codes


PubChem CID  11479259

DrugBank Accession Number  Not available

NCI Thesaurus Code  C142999  

UNII  3382C833Z5   GSRS

CAS  623174-20-9 



Drug approval


Drug indication
    Investigated for use/treatment in Melanoma,Non-Small-Cell Lung Carcinoma, Hormone-refractory Prostate Cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00068211 A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Inoperable Locally Advanced or Metastatic Melanoma. Melanoma Phase 2 Treatment
NCT00082134 A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Every 21 Days in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel Hormone-refractory Prostate Cancer Phase 2 Treatment
NCT00078455 A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma Non-Small-Cell Lung Carcinoma Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.